Ajay Labroo
Interventional Cardiology · Panama City, FLNPI 1831199371
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Novartis at 59.4% of the total. Reporting peaked in 2019 at $6,019 and has fallen 96.3% since, to $225 in 2025.
Across 188 payments — averaging $50.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$6K
- Actelion Pharmaceuticals US, Inc.$702
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$450
- Abbott$327
- Boston Scientific$322
- Amarin Pharma, Inc.$259
- plus $2K from 21 others
Across 6 payments — averaging $1108.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$5K
- Kowa Research Institute, Inc.$1K
- Merck$526
What the payments were for
- Speaking & faculty fees$4,95052%
- Travel & lodging$1091%
- Food & beverage$4,30945%
- Education$1992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 38 | $5,680 |
| Actelion Pharmaceuticals US, Inc. | 22 | $702 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $450 |
| Abbott | 4 | $327 |
| Boston Scientific | 7 | $322 |
| Amarin Pharma, Inc. | 11 | $259 |
| Shockwave Medical, Inc | 4 | $238 |
| Amgen | 12 | $222 |
| Merck | 8 | $175 |
| Philips North America LLC | 2 | $165 |
| Kowa Pharmaceuticals America, Inc. | 12 | $154 |
| E.r. Squibb & Sons, L.L.C. | 8 | $147 |
| Johnson & Johnson | 9 | $127 |
| AstraZeneca | 8 | $108 |
| Bayer | 4 | $75 |
| Opsens Inc. | 2 | $71 |
| Medtronic | 3 | $59 |
| Pfizer | 2 | $54 |
| Aerin Medical Inc. | 1 | $43 |
| Daiichi Sankyo Inc. | 2 | $39 |
| United Therapeutics Corporation | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Impulse Dynamics (USA) Inc. | 1 | $22 |
| Terumo Medical Corporation | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,566 in reported general payments places this provider in the 55th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 17 | $388,050 |
| EntrestoSacubitril/Valsartan | 18 | $22,706 |
| EliquisApixaban | 12 | $16,658 |
| Metoprolol Succinate | 44 | $887 |
| Ramipril | 21 | $282 |
| Atorvastatin Calcium | 24 | $268 |
| Losartan Potassium | 22 | $220 |
| Carvedilol | 29 | $182 |
| Spironolactone | 17 | $180 |
| ClopidogrelClopidogrel Bisulfate | 33 | $158 |
| Amlodipine Besylate | 25 | $138 |
| Nitroglycerin | 11 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $702 | $388,05017 claims |
| NovartisEntresto | $5,680 | $22,70618 claims |
| PfizerEliquis | $54 | $16,65812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Panama City
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.